ClinicalTrials.gg
CompletedNCT06065722Updated Nov 19, 2026

Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

A Phase 2 interventional study of Akynzeo in Chemotherapy Induced Nausea and Vomiting, sponsored by Simon Williamson Clinic. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Simon Williamson Clinic · Phase 2, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was Nov 2024, 1 year 11 months ago, and no results have been posted to the registry.
Updated Nov 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 286 studies in Vomiting with a site in United States — 25 open to participants now, 27 under way, 5 of them phase 3. Vomiting · United States.

Enrollment
113th of 256
100 · median 86
Started
2023
with 6 others
Phase 2
57 of 286
1 open now
Registered
266th of 286
by date

Among the 286 studies in Vomiting with a site in United States, this one is the 113th largest by enrollment of the 256 interventional ones that give a count, is one of 7 that started in 2023, is one of 57 in phase 2, and was the 266th registered.

Vomiting

794 studies on the registry are indexed under Vomiting; 98 are open to participants now.

Browse Vomiting studies →

Open to participants now

25 of the 286 studies in Vomiting with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 57 Vomiting studies recruiting now, 27 (47%) set no upper age limit and 24 (42%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 286 studies in Vomiting with a site in United States, or all of them as a file.
02

Study summary

The purpose of the proposed study is to provide a clinical approach to chemotherapy induced nausea and vomiting (CINV) prophylaxis in cycle 2 of moderately emetogenic chemotherapy or highly emetogenic chemotherapy for patients who developed breakthrough CINV after cycle 1 based on the available data in the literature as well as the recommendations provided by established guidelines

Read the detailed description

Chemotherapy-induced nausea and vomiting (CINV) adversely affects patients' quality of life and may affect patients' treatment decisions. The emetogenicity of the chemotherapy administered and specific patient characteristics such as female gender, age, and history of low alcohol intake can increase a patients' risk for CINV.

Table 1. Patient-Related Risk Factors for Emesis Following Chemotherapy Major Factors Minor Factors Female History of Motion Sickness Age \< 50 years Emesis during past pregnancy History of prior low chronic alcohol intake (\<1 ounce of alcohol/day) Anxiety History of previous chemotherapy-induced emesis

Significant and uncontrolled CINV may result in patients returning to the chemotherapy treatment facility one to three days post-chemotherapy for rehydration, or emesis or nausea control. If CINV cannot be controlled in an outpatient facility, patients may subsequently be treated in an emergency department or require hospitalization. Patients who have an electrolyte imbalance or those who have recently undergone surgery or radiation therapy, are at greater risk of experiencing serious complications from CINV.

The use of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists has improved the control of CINV Additional improvement in the control of CINV has occurred with the use of neurokinin-1 (NK-1) receptor antagonists, and olanzapine, an antipsychotic which blocks multiple neurotransmitters in the central nervous system.

The primary endpoint used for studies evaluating various agents for the control of CINV has been complete response (CR) (no emesis, no use of rescue medication) over the acute (24 hours post-chemotherapy), delayed (24-120 hours), and overall (0-120 hours) periods. The combination of a 5-HT3 receptor antagonist, dexamethasone, and a NK-1 receptor antagonist have improved the control of emesis in patients receiving either highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC) over a 120-hour period following chemotherapy administration

The use of effective antiemetic agents in various clinical settings has been described in established guidelines from the Multinational Association of Supportive Care in Cancer (MASCC) and the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO)], and the National Comprehensive Cancer Network (NCCN).

The purpose of the proposed is to provide a clinical approach to CINV prophylaxis in cycle 2 of MEC or HEC for patients who developed breakthrough CINV after cycle 1 based on the available data in the literature as well as the recommendations provided by established guidelines.

03

Conditions studied

  • Chemotherapy Induced Nausea and Vomiting

Browse trials for

Keywords

  • chemotherapy induced nausea and vomiting
  • NK-1
  • olanzapine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • CHEMOTHERAPY NAIIVE
  • patient receiving moderately or highly emetogenic chemotherapy
  • lung cancer
  • breast cancer

Exclusion criteria

Exclusion Criteria:

  • PRIOR CHEMOTHERAPY for any cancer
  • nausea or vomiting 24 hours prior to study entry
05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Active comparator
    AKYNZEO for patient receiving MEC

    Add Akynzeo to 5HT3 And dexamethasone

    Drug: Akynzeo

  • Active comparator
    oLANZAPINE and Akynzeo to patients receiving highly emetogenic

    olANZAPINE plus Akynzeo

    Drug: Akynzeo

Interventions

  • DrugAkynzeo

    OLANZAPINE

    Also known as: Olanzapine

06

What researchers measure

Primary outcomes

  1. COMPELETE RESPONSE, no vomiting or use of rescue medications

    No vomiting or use of rescue medications for 5 days post chemotherapy

    Time frame: 5 DAYS post chemotherapy

07

Study locations

1 site
  • Rudolph M Navari
    Mount Olive, Alabama 35117, United States
08

References and documents

Publications

  • Navari RM, Bonizzoni E. NEPA (Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial. Cancer Med. 2025 Apr;14(7):e70549. doi: 10.1002/cam4.70549. PubMed 40145359 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Nov 2024, 14 months.

Of 41 phase 2 interventional studies under Vomiting, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 14 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Dec 2023 → Nov 2024 and completion Dec 2023 → Nov 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2023
First posted
Oct 4, 2023
StartActual
Sep 9, 2023
Primary completionActual
Nov 27, 2024was Dec 2023
CompletionActual
Nov 27, 2024was Dec 2023
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 19, 2026
Primary completion
Dec 31, 2023→Nov 27, 2024 (actual)
Nov 19, 2026
Study completion
Dec 31, 2023→Nov 27, 2024 (actual)
Nov 19, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40145359 ↗
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40145359 ↗
    Primary completion Dec 31, 2023→Nov 27, 2024 (now actual)
    Study completion Dec 31, 2023→Nov 27, 2024 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06065722
Lead sponsor
Simon Williamson Clinic
Responsible party
Sponsor
First posted
Oct 4, 2023
Start date
Sep 9, 2023
Primary completion
Nov 27, 2024
Completion
Nov 27, 2024
Last update
Nov 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion